Best Weight Loss Injections for Men in 2026 — Ranked & Reviewed
GLP-1 injections work the same in men and women — semaglutide and tirzepatide dosing is identical — but men's-health platforms wrap them differently: muscle-preservation protocols, testosterone panels alongside metabolic labs, and programs built for a male patient base. We ranked the injectable GLP-1 providers with genuine men's-health focus by price, clinical oversight, and transparency.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Quick Picks: Top 5
Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →
Detailed Reviews
Enhance MD
Verified partnerBest for: lab-monitored compounded GLP-1 with mandatory video visit
Enhance MD pairs compounded semaglutide and tirzepatide with mandatory baseline metabolic labs at Quest Diagnostics and a synchronous video visit with a board-certified clinician — a more rigorous onboarding than the async-only compounded GLP-1 model most telehealth providers use. Three tiers (Core semaglutide, Advanced tirzepatide, Elite combined) plus aggressive intro pricing ($49 first month on Core).
Score Breakdown
Pros
- ✓Baseline and ongoing metabolic labs (CMP, lipids, TSH, HbA1c) at Quest every 6 months — rare for compounded GLP-1
- ✓Mandatory video visit with a US-licensed MD or NP before your first prescription — not a pure questionnaire model
- ✓Three tiers, including a combined semaglutide + tirzepatide Elite plan ($322/mo) for patients plateaued on one GLP-1
- ✓Uses LegitScript-certified 503A pharmacies (Tru Meds Rx, Strive Pharmacy, Pharmacy Hub)
- ✓Low first-month intro pricing: $49 Core, $99 Advanced, $189 Elite
- ✓Unlimited clinician messaging and dose-adjustment support included
Cons
- ✗Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
- ✗Not available in 10 states: AL, AR, GA, HI, LA, MS, MO, SC, TN, WV
- ✗Mandatory lab work adds 5–10 days to onboarding vs async-only competitors
- ✗No insurance accepted — cash pay, HSA/FSA eligible
- ✗Intro pricing resets to full tier rate after 30 days — the $49/$99/$189 figures aren't ongoing cost
Embody
Verified partnerBest for: lowest first-month entry pricing on compounded GLP-1s
Embody offers compounded semaglutide and tirzepatide via injection plus a unique compounded oral tirzepatide gum formulation. Aggressive first-month entry pricing with all 50 states and a 24/7 clinician messaging model led by a board-certified internal medicine CMO.
Score Breakdown
Pros
- ✓Lowest first-month entry pricing in the compounded segment ($99 first month for semaglutide, $149 for tirzepatide injection)
- ✓Unique compounded oral tirzepatide gum formulation — alternative for patients who prefer not to inject
- ✓Available in all 50 states with no insurance friction
- ✓24/7 unlimited clinician messaging and dose-adjustment support included
- ✓Medical leadership by Dr. Alan Viglione, board-certified in Internal Medicine
Cons
- ✗Refill pricing jumps to $299/month after the first month — initial $99/$149 is an intro rate, not the ongoing cost
- ✗Compounded only — no FDA-approved brand-name Ozempic, Wegovy, Zepbound, or Mounjaro option
- ✗Pharmacy partners not publicly named — compounding source transparency is limited
- ✗Compounded oral tirzepatide does not have an FDA-approved counterpart, and oral GLP-1 bioavailability remains an active area of clinical debate
DudeMeds
Verified partnerBest for: men seeking no-fee GLP-1 access with oral and injectable options
DudeMeds is a men's telehealth platform offering semaglutide and tirzepatide in both oral and injectable formats from $149/month. No membership fee, no doctor fee, free shipping. Also offers TRT, ED, and hair loss treatments. Accepts clinic-switch patients from existing GLP-1 and TRT providers.
Score Breakdown
Pros
- ✓Semaglutide and tirzepatide in both oral and injectable forms
- ✓No membership or doctor fee, free shipping — all-in pricing from $149/mo
- ✓HSA and FSA eligible
- ✓Accepts patients switching from existing GLP-1 and TRT providers
- ✓Async consultations in most states — no video visit required
- ✓24/7 patient portal for ongoing care and dose adjustments
Cons
- ✗Men's-only branding may not appeal to women
- ✗State availability not published — described only as 'most states'
- ✗No visible LegitScript certification or PCAB accreditation
- ✗Newer brand with limited independent reviews
- ✗Dose-tier pricing beyond the $149 starting price isn't disclosed
PeterMD
Verified partnerBest for: men seeking flat-priced compounded GLP-1 access alongside TRT or peptide therapy
PeterMD is a men's telehealth platform offering compounded GLP-1 weight loss medications (semaglutide and tirzepatide, often with B12). Also covers TRT, peptide therapy, sexual health, and anti-aging treatments. Transparent monthly pricing with no insurance required.
Score Breakdown
Pros
- ✓Flat pricing across semaglutide dose tiers (0.25mg through 2.4mg)
- ✓Both semaglutide and tirzepatide available
- ✓Month-to-month cancellation via patient portal, no cancellation fee
- ✓Covers men's-health adjacencies (TRT, peptides, ED, anti-aging) in one account
- ✓Compounded semaglutide at a flat $105/mo billed monthly — among the lowest in the category
Cons
- ✗Not available in 8 states (AL, AR, CA, HI, ID, MI, NC, TX)
- ✗Men's-only branding — will not appeal to women seeking GLP-1 access
- ✗Pharmacy partner and named clinicians not publicly disclosed
- ✗Tirzepatide is billed quarterly at $249/mo — you commit to a ~3-month charge upfront
Maximus
Verified partnerBest for: men seeking compounded GLP-1 alongside testosterone optimization
Maximus is a men's health platform offering compounded semaglutide (from ~$99/mo) and compounded tirzepatide alongside testosterone replacement therapy and longevity treatments. Available in all 50 states + DC. Microdose protocol available for patients with less weight to lose.
Score Breakdown
Pros
- ✓All 50 states + DC coverage
- ✓Microdose GLP-1 protocol for patients with less weight to lose
- ✓Established men's health brand
- ✓Semaglutide from $149.99/mo and tirzepatide from $249.99/mo, flat-rate plans including all dose tiers
Cons
- ✗No LegitScript or PCAB certification found
- ✗BBB F rating reported by third-party reviewers — complaints about unfulfilled prescriptions
- ✗Men's health platform — TRT is the core product, GLP-1 is secondary
- ✗Compounded only — no brand-name options
How to choose a GLP-1 provider as a man
GLP-1 dosing is identical for men and women — but men's-health platforms wrap it differently. The differences worth paying for are muscle preservation, hormone-aware monitoring, and honest results expectations.
What to look for
- Muscle-preservation focus. Men often want to lose fat while keeping strength. Favor providers that pair the GLP-1 with protein guidance and resistance-training support rather than medication alone.
- Hormone-aware monitoring. Significant weight loss can shift testosterone. Some men's-health providers run hormone panels alongside metabolic labs — useful if that's a concern for you.
- Effective dose, honest expectations. Tirzepatide outperforms semaglutide on average for weight loss. A good provider is candid about that trade-off (and cost) instead of pushing whichever it happens to stock.
Red flags to avoid
- No named pharmacy or LegitScript listing. A legitimate compounded-GLP-1 provider names its 503A/503B pharmacy partner and carries LegitScript certification. If neither is disclosed, you can't verify what you're injecting.
- Async-only, no real clinician review. A prescriber should review your intake and be reachable for dose questions. Instant approval with no way to reach a clinician is a safety gap.
- Teaser pricing that hides the real cost. A low 'first month' price that jumps at higher doses, or a membership fee stacked on top of the medication, can double the true monthly total. Confirm the ongoing, all-in price before you pay.
- Weight-loss claims for B12, MIC, or HCG shots. Only GLP-1 injections have trial evidence for weight loss. A clinic selling B12, lipotropic, or HCG shots as a weight-loss treatment is a red flag.
Every provider ranked above is scored against these criteria across our six-dimension methodology, and prices are re-verified against each provider’s live site.
How we rank & what counts as “legit”
Every provider in this ranking is scored against our published six-factor rubric[1] — value, effectiveness, user experience, trust & safety, accessibility, and support.
Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro are separately FDA-approved under their own NDA numbers[4][5]. Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial[6], and for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) from SURMOUNT-1[7]; the SURMOUNT-5 head-to-head published in 2025 compared the two directly[8].
Insurance coverage for anti-obesity medications varies widely by state Medicaid program and commercial plan[9][10]. Compounded and brand-name GLP-1s are generally FSA/HSA eligible with a prescription under IRS Publication 502[11].
Related Rankings
Frequently Asked Questions
Sources & methodology — as of July 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.